[go: up one dir, main page]

BR9807009A - Composition for administration of steroid drug transfer - Google Patents

Composition for administration of steroid drug transfer

Info

Publication number
BR9807009A
BR9807009A BR9807009-6A BR9807009A BR9807009A BR 9807009 A BR9807009 A BR 9807009A BR 9807009 A BR9807009 A BR 9807009A BR 9807009 A BR9807009 A BR 9807009A
Authority
BR
Brazil
Prior art keywords
composition
administration
steroid drug
drug transfer
steroid
Prior art date
Application number
BR9807009-6A
Other languages
Portuguese (pt)
Inventor
Cheol Moon
Je-Phil Ryoo
Mi-Suk Choi
Jong-Kun Choi
Original Assignee
Lg Chemical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lg Chemical Ltd filed Critical Lg Chemical Ltd
Publication of BR9807009A publication Critical patent/BR9807009A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

"COMPOSIçãO PARA ADMINISTRAçãO TRANSDéRMICA DE MEDICAMENTOS ESTERóIDES". Composição para administração transdérmica de um medicamento esteróide contendo uma quantidade terapeuticamente eficaz de um medicamento; um promotor de absorção consistindo essencialmente de éter dietileno glico e um éster sorbitan e uma matriz adesiva famaceuticamente aceitável."COMPOSITION FOR TRANSDERMAL ADMINISTRATION OF STEROID MEDICINES". Composition for transdermal administration of a steroid drug containing a therapeutically effective amount of a drug; an absorption promoter consisting essentially of diethylene glycol ether and a sorbitan ester and a pharmaceutically acceptable adhesive matrix.

BR9807009-6A 1997-01-27 1998-01-23 Composition for administration of steroid drug transfer BR9807009A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1019970002233A KR100215027B1 (en) 1997-01-27 1997-01-27 Composition for transdermal administration of steroid drugs and formulation containing same
PCT/KR1998/000013 WO1998032465A1 (en) 1997-01-27 1998-01-23 Composition for the transdermal administration of steroid drugs

Publications (1)

Publication Number Publication Date
BR9807009A true BR9807009A (en) 2000-03-14

Family

ID=19495561

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9807009-6A BR9807009A (en) 1997-01-27 1998-01-23 Composition for administration of steroid drug transfer

Country Status (12)

Country Link
EP (1) EP1001812A1 (en)
JP (1) JP2000508349A (en)
KR (1) KR100215027B1 (en)
CN (1) CN1244806A (en)
AR (1) AR011577A1 (en)
AU (1) AU727811B2 (en)
BR (1) BR9807009A (en)
CA (1) CA2277970A1 (en)
ID (1) ID19755A (en)
RU (1) RU2176499C2 (en)
TW (1) TW537899B (en)
WO (1) WO1998032465A1 (en)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100294084B1 (en) * 1998-06-02 2001-09-22 성재갑 Composition for transdermal administration of non-steroid drugs and formulation containing same
AU2223600A (en) * 1999-01-06 2000-07-24 Cedars-Sinai Medical Center Hormone replacement for breast cancer patients
KR100403051B1 (en) * 2000-07-25 2003-10-23 일양약품주식회사 Composition of matrix type patch for transdermal testosterone delivery and process for preparing the same
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
DE10107663B4 (en) * 2001-02-19 2004-09-09 Lts Lohmann Therapie-Systeme Ag Testosterone-containing transdermal therapeutic system, process for its preparation and its use
DE10163459A1 (en) * 2001-12-21 2003-07-03 Merck Patent Gmbh Lyophilized preparation containing antibodies to EGF receptor
FR2848112B1 (en) * 2002-12-10 2007-02-16 Besins Int Belgique PHARMACEUTICAL COMPOSITION FOR TRANSDERMAL OR TRANSMUCTIVE DELIVERY COMPRISING AT LEAST ONE PROGESTATIVE AND / OR AT LEAST ONE OESTROGEN, PREPARATION METHOD AND USES THEREOF
AU2003296810A1 (en) * 2002-12-10 2004-07-09 Besins International Belgique Pharmaceutical composition for transdermal or transmucous administration comprising a progestin or an estrogen, method for preparing same and uses thereof
FR2851470B1 (en) 2003-02-20 2007-11-16 Besins Int Belgique PHARMACEUTICAL COMPOSITION FOR TRANSDERMAL OR TRANSMUCTIVE DELIVERY
JP4422430B2 (en) * 2003-05-14 2010-02-24 帝國製薬株式会社 External patch containing estrogen and / or progestogen
GB0409498D0 (en) * 2004-04-28 2004-06-02 Hunter Fleming Ltd Transdermal steroid formulation
CN1313084C (en) * 2004-11-05 2007-05-02 郑会义 Percutaneous contraceptive drugs delivery system and method
DE102004059880A1 (en) * 2004-12-10 2006-06-14 Grünenthal GmbH Stable, hormone-containing (intermediate) product
JP4969050B2 (en) * 2005-01-07 2012-07-04 ロート製薬株式会社 Topical skin preparation
JP2007045808A (en) * 2005-01-07 2007-02-22 Rohto Pharmaceut Co Ltd Skin care preparation
US10080760B2 (en) 2009-10-27 2018-09-25 Besins Healthcare Luxembourg Sarl Transdermal pharmaceutical compositions comprising active agents
JP6004364B2 (en) * 2011-10-14 2016-10-05 大正製薬株式会社 Topical skin preparation
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
EP3936133A1 (en) 2011-11-23 2022-01-12 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
JP5521025B2 (en) * 2012-12-21 2014-06-11 日本精化株式会社 Penetration enhancer
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10206932B2 (en) 2014-05-22 2019-02-19 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
CA3020153A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
KR101968873B1 (en) * 2018-09-21 2019-04-29 아이큐어 주식회사 Cosmetic composition comprising peptide derived from Botulinum toxin having improved cell penetrating ability

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4291015A (en) * 1979-08-14 1981-09-22 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing a vasodilator
JPH0744940B2 (en) * 1986-12-24 1995-05-17 ライオン株式会社 Base material for oral application
CH674618A5 (en) * 1987-04-02 1990-06-29 Ciba Geigy Ag
CA1333114C (en) * 1987-11-25 1994-11-15 Daniel C. Duan Pressure-sensitive adhesives and bioelectrodes constructed with the adhesive
US4906475A (en) * 1988-02-16 1990-03-06 Paco Pharmaceutical Services Estradiol transdermal delivery system
ATE132751T1 (en) * 1988-10-27 1996-01-15 Schering Ag AGENTS FOR TRANSDERMAL APPLICATION CONTAINING STODENE
DE3910578A1 (en) * 1989-03-29 1990-10-04 Schering Ag Composition for transdermal administration containing gestodene
US4973468A (en) * 1989-03-22 1990-11-27 Cygnus Research Corporation Skin permeation enhancer compositions
ATE107517T1 (en) * 1989-05-25 1994-07-15 Takeda Chemical Industries Ltd TRANSDERMAL THERAPEUTIC AGENT.
US5314685A (en) * 1992-05-11 1994-05-24 Agouron Pharmaceuticals, Inc. Anhydrous formulations for administering lipophilic agents

Also Published As

Publication number Publication date
AR011577A1 (en) 2000-08-30
CA2277970A1 (en) 1998-07-30
KR100215027B1 (en) 1999-08-16
CN1244806A (en) 2000-02-16
JP2000508349A (en) 2000-07-04
AU5882098A (en) 1998-08-18
TW537899B (en) 2003-06-21
ID19755A (en) 1998-07-30
EP1001812A1 (en) 2000-05-24
RU2176499C2 (en) 2001-12-10
WO1998032465A1 (en) 1998-07-30
AU727811B2 (en) 2000-12-21
KR19980066583A (en) 1998-10-15

Similar Documents

Publication Publication Date Title
BR9807009A (en) Composition for administration of steroid drug transfer
AU2833195A (en) Compositions for topical administration of anesthetic agents
AR034518A1 (en) INCREASE IN THE TRANSDERMAL ADMINISTRATION OF A PHARMACO
ES2152979T3 (en) TRANSDERMAL THERAPEUTIC SYSTEM CONTAINING ESTRADIOL.
CA2153572A1 (en) Transdermal therapeutic system with galanthamine as active ingredient
EE9700241A (en) Pharmaceutical composition for transdermal administration
DK0642788T3 (en) Tramadol-containing drug with delayed release of active substance
NZ509418A (en) Pharmaceutical formulations for aerosols with two or more active substances
IT1283102B1 (en) THERAPEUTIC COMPOSITION FOR THE TRANSDERMAL ADMINISTRATION OF AN ESTROGENIC OR PROGESTINIC ACTIVE SUBSTANCE OR OF THEIR MIXTURES
AR004179A1 (en) SALTS OF (ENDO, SIN) - (-) - 3- (3-HIDROXI-1-OXO-2-FENILPROPOXI) -8-METHYL-8- (1- METHYLETIL) -8-AZONIABICYCLE [3.2.1] OCTANO AND INHALATIVE DRUG PREPARATIONS CONTAINING THEM.
BR9604880A (en) Compound composition dosage unit form methods for administering a biologically active agent for preparing a composition for administering an active agent and for preparing a compound and pharmacological composition
AR012376A1 (en) GEL FORMULATION FOR TOPIC APPLICATION
BR9708706B1 (en) pharmaceutical composition for intravenous administration to a patient
AU1819288A (en) Pharmaceutical composition for percutaneous drug absorption and percutaneous drug absorption promoter
GT199700037A (en) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF RHINITIS
IL127572A (en) Pharmaceutical composition and medicament for nasal administration
DE69602759D1 (en) PHARMACEUTICAL COMPOSITIONS AND DEVICES FOR THEIR ADMINISTRATION
YU17899A (en) Pharmaceutical microspheres of valproic acid for oral administration
GB2305606B (en) Drug delivery composition for the nasal administration of ICAM-1
CA2148112A1 (en) New pharmaeutical dosage form for transdermal administration
NO993435L (en) Transdermal acetylsalicylic acid containing therapeutic system with enhanced resorption
ES2161809T3 (en) USE OF OSTEOBLASTIC PROLIFERATIVE FACTOR.
PT944384E (en) SYSTEM FOR TRANSDERMIC ADMINISTRATION OF DRUGS FOR THE TREATMENT OF CORACAO DISEASES
AR012637A1 (en) DERIVATIVES OF PREGNANE, A PHARMACEUTICAL COMPOSITION AND THE USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT.
AR014096A1 (en) 17 ALPHA, 8,9-DEHYDROESTRADIOL AND 17 BETA DELTA 8,9 DEHYDROESTRADIOL, THE USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT, A COMPOSITION PHARMACEUTICAL COMPOSITION AND A PROCEDURE FOR PREPARATION.

Legal Events

Date Code Title Description
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements